Taysha Announces Pricing of Public Offering of Common Stock
October 26 2022 - 7:54PM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a
patient-centric, pivotal-stage gene therapy company focused on
developing and commercializing AAV-based gene therapies for the
treatment of monogenic diseases of the central nervous system (CNS)
in both rare and large patient populations, today announced the
pricing of an underwritten public offering of 14,000,000 shares of
its common stock at a price to the public of $2.00 per share. In
addition, Taysha has granted the underwriter a 30-day option to
purchase up to 2,100,000 additional shares of common stock at the
public offering price, less the underwriting discount. The gross
proceeds from the offering to Taysha are expected to be
approximately $28.0 million, before deducting underwriting
discounts and commissions and other offering expenses, excluding
any exercise of the underwriter’s option to purchase additional
shares. The offering is expected to close on or about October 31,
2022, subject to customary closing conditions.
Goldman Sachs & Co. LLC is acting as sole book-runner for
the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (the “SEC”) on October 5,
2021 and declared effective by the SEC on October 14, 2021. The
offering is being made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to the offering has been filed with the SEC and
is available on the SEC’s website at www.sec.gov. A final
prospectus supplement and accompanying prospectus will be filed
with the SEC. When available, copies of the final prospectus
supplement and the accompanying prospectus may also be obtained by
contacting Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by telephone at
(866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, Taysha aims to rapidly translate its
treatments from bench to bedside. Taysha has combined its team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, Taysha leverages
its fully integrated platform—an engine for potential new
cures—with a goal of dramatically improving patients’ lives.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,”
“intends,” “projects,” “plans,” and “future” or similar expressions
are intended to identify forward-looking statements.
Forward-looking statements include statements concerning the
potential of Taysha’s candidates, including its preclinical product
candidates, to positively impact quality of life and alter the
course of disease in the patients Taysha seeks to treat, its
research, development and regulatory plans for its product
candidates, and Taysha’s public offering, including expected gross
proceeds and anticipated closing date, the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all. Forward-looking statements are based
on management’s current expectations and are subject to various
risks and uncertainties that could cause actual results to differ
materially and adversely from those expressed or implied by such
forward-looking statements. Accordingly, these forward-looking
statements do not constitute guarantees of future performance, and
you are cautioned not to place undue reliance on these
forward-looking statements. Risks regarding Taysha’s business are
described in detail in its SEC filings, including in Taysha’s
Annual Report on Form 10-K for the full-year ended December 31,
2021, and Taysha’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2022, both of which are available on the SEC’s
website at www.sec.gov. Additional information will be made
available in other filings that Taysha makes from time to time with
the SEC. Such risks may be amplified by the impacts of the COVID-19
pandemic. These forward-looking statements speak only as of the
date hereof, and Taysha disclaims any obligation to update these
statements except as may be required by law.
Company Contact: Kimberly Lee, D.O. Chief
Corporate Affairs Officer Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Evoke Canale
carolyn.hawley@evokegroup.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Oct 2023 to Oct 2024